References
- Laugesen K, Jørgensen JOL, Petersen I, Sørensen HT. Fifteen-year
nationwide trends in systemic glucocorticoid drug use in Denmark.Eur J Endocrinol . 2019;181(3):267-273.
- Prescription cost analysis. England 2018.
https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/2018
Last accessed 3/7/20
- Rhen T, Cidlowski JA. Antiinflammatory action of
glucocorticoids–new mechanisms for old drugs. N Engl J Med .
2005;353(16):1711-1723.
- Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and
therapeutic index. Br J Clin Pharmacol . 2015;80(3):372-380.
- British National Formulary. Glucocorticoid and mineralocorticoid
activity.
https://bnf.nice.org.uk/treatment-summary/glucocorticoid-therapy.html
Last accessed 3/7/20
- British National Formulary. Topical corticosteroids.
https://bnf.nice.org.uk/treatment-summary/topical-corticosteroids.html
Last accessed 3/7/20
- Judd LL, Schettler PJ, Brown ES, Wolkowitz OM, Sternberg EM, Bender
BG, Bulloch K, Cidlowski JA, de Kloet ER, Fardet L, Joëls M, Leung DY,
McEwen BS, Roozendaal B, Van Rossum EF, Ahn J, Brown DW, Plitt A,
Singh G. Adverse consequences of glucocorticoid medication:
psychological, cognitive, and behavioral effects. Am J Psychiatry.
2014;171(10):1045-51.
- Waljee AK, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM, Ayanian
JZ, Nallamothu BK. Short term use of oral corticosteroids and related
harms among adults in the United States: population based cohort
study. BMJ. 2017;357:j1415.
- Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V,
Kovac SH, Spettell CM, Saag KG. Population-based assessment of adverse
events associated with long-term glucocorticoid use. Arthritis Rheum.
2006;55(3):420-6.
- Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral
corticosteroids and risk of fractures. J Bone Miner Res .
2000;15(6):993-1000.
- Laan RF, van Riel PL, van de Putte LB, van Erning LJ, van’t Hof MA,
Lemmens JA. Low-dose prednisone induces rapid reversible axial bone
loss in patients with rheumatoid arthritis. A randomized, controlled
study. Ann Intern Med . 1993;119(10):963-968.
- MacGregor AJ, Dhillon VB, Binder A, Forte CA, Knight BC, Betteridge
DJ, Isenberg DA. Fasting lipids and anticardiolipin antibodies as risk
factors for vascular disease in systemic lupus erythematosus. Ann
Rheum Dis. 1992;51(2):152-5
- Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R, Zink
A, Buttgereit F. Dose-related patterns of glucocorticoid-induced side
effects. Ann Rheum Dis. 2009;68(7):1119-24.
- Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, Inês LB, de
Koning EJ, Buttgereit F, Cutolo M, Capell H, Rau R, Bijlsma JW. Safety
of low dose glucocorticoid treatment in rheumatoid arthritis:
published evidence and prospective trial data. Ann Rheum Dis.
2006;65(3):285–93.
- Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription
is associated with subsequent cardiovascular disease. Ann Intern
Med . 2004;141(10):764-770.
- Esteban NV, Loughlin T, Yergey AL, Zawadzki JK, Booth JD, Winterer JC,
Loriaux DL. Daily cortisol production rate in man determined by stable
isotope dilution/mass spectrometry. J Clin Endocrinol Metab .
1991;72(1):39-45.
- Chan S, Debono M. Replication of cortisol circadian rhythm: new
advances in hydrocortisone replacement therapy. Ther Adv
Endocrinol Metab . 2010;1(3):129-138. doi:10.1177/2042018810380214
- Streck, W.F.; Lockwood, D.H. Pituitary adrenal recovery following
short-term suppression with corticosteroids. Am. J. Med. 1979, 66,
910–914
- Nicolaides NC, Pavlaki AN, Maria Alexandra MA, Chrousos GP.
Glucocorticoid Therapy and Adrenal Suppression. [Updated 2018 Oct
19]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext
[Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
Available from: https://www.ncbi.nlm.nih.gov/books/NBK279156/
Last accessed 3/7/20
- Jasani MK, Boyle JA, Greig WR, Dalakos TG, Browning MC, Thompson A,
Buchanan WW. Corticosteroid-induced suppression of the
hypothalamo-pituitary-adrenal axis: observations on patients given
oral corticosteroids for rheumatoid arthritis. Q J Med. 1967
Jul;36(143):261-76.
- Mendoza-Cruz, A.C.; Wargon, O.; Adams, S.; Tran, H.; Verge, C.F.
Hypothalamic-pituitary-adrenal axis recovery following prolonged
prednisolone therapy in infants. J. Clin. Endocrinol. Metab. 2013, 98,
E1936–E1940.
- Joseph RM, Hunter AL, Ray DW, Dixon WG. Systemic glucocorticoid
therapy and adrenal insufficiency in adults: A systematic review.Semin Arthritis Rheum . 2016;46(1):133-141.
- Broersen LH, Pereira AM, Jørgensen JO, Dekkers OM. Adrenal
Insufficiency in Corticosteroids Use: Systematic Review and
Meta-Analysis. J Clin Endocrinol Metab . 2015;100(6):2171-2180.
- Furst DE, Matteson EL, Ramirez Curtis M. Glucocorticoid withdrawal.
https://www.uptodate.com/contents/glucocorticoid-withdrawal Last
accessed 3/7/20
- NICE clinical knowledge summaries. Scenario: Management of polymyalgia
rheumatica
https://cks.nice.org.uk/polymyalgia-rheumatica#!scenarioRecommendation
Last accessed 3/7/20
- Robson JC, Dawson J, Cronholm PF, Ashdown S, Easley E, Kellom KS,
Gebhart D, Lanier G, Milman N, Peck J, Luqmani RA, Shea JA, Tomasson
G, Merkel PA. Patient perceptions of glucocorticoids in
anti-neutrophil cytoplasmic antibody-associated vasculitis.Rheumatol Int . 2018;38(4):675-682.
- Prasad GV, Nash MM, McFarlane PA, Zaltzman JS. Renal transplant
recipient attitudes toward steroid use and steroid withdrawal.Clin Transplant . 2003;17(2):135-139.
- Carella MJ, Srivastava LS, Gossain VV, Rovner DR.
Hypothalamic-pituitary-adrenal function one week after a short burst
of steroid therapy. J Clin Endocrinol Metab .
1993;76(5):1188-1191.
- Schuetz P, Christ-Crain M, Schild U, Süess E, Facompre M, Baty F,
Nusbaumer C, Brutsche M, Müller B. Effect of a 14-day course of
systemic corticosteroids on the hypothalamic-pituitary-adrenal-axis in
patients with acute exacerbation of chronic obstructive pulmonary
disease. BMC Pulm Med . 2008;8:1
- British National Formulary. Prednisolone. Treatment Cessation.
https://bnf.nice.org.uk/drug/prednisolone.html#treatmentCessationInformation
Last accessed 3/7/20
- Addison’s self-help group. Newly diagnosed – Sick day rules
https://www.addisonsdisease.org.uk/newly-diagnosed-sick-day-rules
Last accessed 3/7/20
- Giordano R, Guaraldi F, Mazzoli M, Ghigo E. Do glucocorticoids induce
addiction in humans?. J Endocrinol Invest . 2017;40(8):881-883
- Hochberg Z, Pacak K, Chrousos GP. Endocrine withdrawal syndromes.
Endocr Rev. 2003;24(4):523-38
- Fardet L, Nazareth I, Whitaker HJ, Petersen I: Severe neuropsychiatric
outcomes following discontinuation of long-term glucocorticoid
therapy: a cohort study. J Clin Psychiatry 2013; 74:e281–e286
- Goldfarb EV, Sinha R. Drug-Induced Glucocorticoids and Memory for
Substance Use. Trends Neurosci. 2018 Nov;41(11):853-868.
- Anfinson TJ, Channappa C, Vo HT. Drug dependence involving prednisone:
two cases and a review of the literature. Psychopharmacol Bull.
2008;41(1):154-63.
- Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with
different types of oral corticosteroids and effect of termination of
corticosteroids on the risk of fractures. Calcif Tissue Int .
2008;82(4):249-257.
- NHS. Coping with side effects of steroid tablets.
https://www.nhs.uk/conditions/steroid-tablets/#side-effects
Last accessed 3/7/20
- NICE guideline [NG100] Rheumatoid arthritis in adults: management
https://www.nice.org.uk/guidance/ng100/chapter/Recommendations#initial-pharmacological-management
Last accessed 3/7/20
- NICE guideline [NG115] Chronic obstructive pulmonary disease in
over 16s: diagnosis and management
https://pathways.nice.org.uk/pathways/chronic-obstructive-pulmonary-disease#path=view%3A/pathways/chronic-obstructive-pulmonary-disease/stable-copd-oral-therapy.xml&content=view-node%3Anodes-corticosteroids
Last accessed 3/7/20
- Walters JAE, Walters EH, Wood-Baker R. Oral corticosteroids for stable
chronic obstructive pulmonary disease. Cochrane Database of Systematic
Reviews 2005, Issue 3. Art. No.: CD005374.